Because trailing earnings are negative, the negative P/E carries no informational content; the more telling signal is P/B of 3.73 against an equity base that prior balance sheet data show has eroded roughly 82% to $71.8M, meaning the market is still paying several times book for a shrinking capital base. The P/S of 2.25 similarly appears anchored to the $108.0M revenue quarter rather than a run-rate, so if milestone recognition normalizes to trough quarters like 2026Q1's $6.4M, the effective multiple would compress sharply. Compared with SGMO and RCKT — both trading near or below book with negative ROIC — RGNX appears priced for a pipeline outcome, an interpretation investors should treat as unvalidated rather than implied by the current multiples.

The negative gross margins suggest revenue-cost recognition is being matched on an event basis rather than period basis, so no single reported margin is a reliable read on underlying economics; the 2026Q2 operating margin of 27.1% should be read against the -$57.6M operating loss implied by 2025Q4's -190.0% margin. FCF margin of -58.3% in the same quarter in which net margin printed 21.0% indicates that even profitable quarters do not convert to cash, which suggests reported net income is a poor proxy for true earning power for this company. Compared with Krystal Biotech's steady gross margin above 90% and positive net margin, RGNX's profitability profile appears structurally unproven rather than temporarily depressed.

The nine-quarter pattern before 2026Q2 shows ROIC persistently negative, ranging from -30.8% to -9.4%, so the single 24.2% print is better treated as an outlier driven by one revenue event than as evidence of compounding returns on capital. Asset turnover peaked at only 0.30 in 2026Q2 versus 0.02–0.06 in most quarters, confirming that capital deployment — including the roughly $142.3M of remaining net PP&E — has generated little revenue throughput across the cycle. For an analyst, the judgment-relevant point is that ROIC has not demonstrated a positive trend line that would justify reinvestment narratives; investors should monitor whether sequential quarters sustain positive ROIC without further equity drawdown.

The extreme DPO print appears inconsistent with a conventional supplier relationship and, alongside the negative $103.3M working capital change recorded in the same profitable quarter, implies the cash conversion cycle cannot be reliably reconstructed from these filings since DIO is unavailable throughout the series. DSO ranging between 21 and 270 days across ten quarters suggests receivable timing around royalty or milestone settlements rather than recurring product billing, which matters because that pattern would not produce a predictable cash cycle in future quarters. Analysts should treat the CCC as data unavailable rather than extrapolated, and instead anchor on the observed OCF-to-net-income gap of -2.74 in 2026Q2 as the more decision-useful conversion metric.

Coverage of 3.91x rests on a single profitable quarter whose earnings prior analysis attributes to revenue timing; the series' deeply negative coverage readings in 2024 (-117x to -31x) indicate that debt service comfort has historically been absent, and the capital structure's swing from 0.28 to 3.37 D/E within two years suggests financing decisions have been reactive to liquidity needs. With equity down roughly 82% over the series, the same nominal debt load now carries meaningfully more balance-sheet weight, so covenant headroom and refinancing terms warrant closer scrutiny than the headline D/E implies. Relative to RCKT's 0.09 D/E, RGNX still carries more leverage for an unprofitable clinical-stage peer, which may constrain its flexibility if milestone revenue disappoints again.